Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M200 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | OTHER | Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk |
| Cohort 2 | OTHER | liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk |
| Group A | OTHER | liposomal doxorubicin, 40 mg/m2 q4wk |
| Group B | OTHER | liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule) |
| Group C | OTHER | liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule) |
| Name | Type | Description |
|---|---|---|
| M200 (Volociximab) | DRUG | 7.5 mg/kg, IV infusion every week until disease progression |
| Liposomal Doxorubicin | DRUG | 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12. |
Inclusion Criteria: * Females aged \>= 18 years old at the time of informed consent. * Advanced (Stage III or IV) histologically documented epithelial ovarian cancer or primary peritoneal cancer (excluding small, round-cell histologies). * Recurrent or persistent disease. * Received no more than 2 ...
M200 is an investigational small molecule being studied for the treatment of non-small cell lung cancer, ovarian cancer, and primary peritoneal cancer. It is in Phase 1 clinical development and has not been approved by the FDA.
M200 is being developed by AbbVie Inc. (ticker: ABBV). The drug is currently in Phase 1 clinical trials for oncology indications.
M200 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for M200 have been completed.
M200 has been studied in two completed Phase 1 trials: NCT00635193, which evaluated M200 in combination with liposomal doxorubicin in ovarian cancer and primary peritoneal cancer, and NCT00654758, which studied M200 with carboplatin and paclitaxel in non-small cell lung cancer.
Yes, M200 is also known as volociximab. Clinical trial NCT00635193 is titled 'Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)', confirming that M200 and volociximab refer to the same drug.